LakeShore Biopharma Gets Nasdaq Delisting Notification
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 12 2025
0mins
Nasdaq Compliance Notification: LakeShore Biopharma received a determination letter from Nasdaq stating it is not in compliance with Listing Rule 5550(a)(2) due to its ordinary shares closing below $1.00 for 30 consecutive business days.
Delisting Consequences: The company is ineligible for the standard 180-day compliance period because it executed a reverse stock split within the past year, leading to a decision to delist its securities effective September 22, 2025, unless an appeal is filed.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
